Our Global IP
Airway Therapeutics maintains a robust global IP estate, with issued patents extending through 2039. Our patents cover sequence variants, formulation technologies, and methods of use across neonatal, pediatric, and adult indications. Protection is further reinforced by proprietary analytics, human cell lines and trade secrets, ensuring long-term differentiation and sustained exclusivity.
Zelpultide alfa is the only recombinant surfactant protein D (SP-D) therapy in late-stage development for BPD prevention, giving it a first-mover advantage and positioning it to become the standard of care. With no other preventive or therapeutic options for BPD currently in the clinic, and the potential for a broad label across inflammatory and infectious diseases, zelpultide alfa is well poised to drive a step change in the market.
